Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).

导出 OA

翻译打印收藏纠错

第一作者： Barry J,Byrne

第一单位： University of Florida, Gainesville, FL, USA. barry.byrne@ufl.edu.

作者： Barry J,Byrne ^[1] ; Benedikt,Schoser ^[2] ; Priya S,Kishnani ^[3] ; Drago,Bratkovic ^[4] ; Paula R,Clemens ^[5] ; Ozlem,Goker-Alpan ^[6] ; Xue,Ming ^[7] ; Mark,Roberts ^[8] ; Matthias,Vorgerd ^[9] ; Kumaraswamy,Sivakumar ^[10] ; Ans T,van der Ploeg ^[11] ; Mitchell,Goldman ^[12] ; Jacquelyn,Wright ^[12] ; Fred,Holdbrook ^[12] ; Vipul,Jain ^[12] ; Elfrida R,Benjamin ^[12] ; Franklin,Johnson ^[12] ; Sheela Sitaraman,Das ^[12] ; Yasmine,Wasfi ^[12] ; Tahseen,Mozaffar ^[13]

作者单位： University of Florida, Gainesville, FL, USA. barry.byrne@ufl.edu. ^[1] Friedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany. ^[2] Duke University Medical Center, Durham, NC, USA. ^[3] PARC Research Clinic, Royal Adelaide Hospital, Adelaide, SA, Australia. ^[4] Department of Neurology, University of Pittsburgh School of Medicine and VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. ^[5] Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, USA. ^[6] Neurology, Rutgers New Jersey Medical School, Newark, NJ, USA.;Guam Regional Medical City, Dededo, Guam. ^[7] Salford Royal NHS Foundation Trust, Salford, UK. ^[8] Department of Neurology, University Hospital Bergmannsheil, Heimer Institute for Muscle Research, Bochum, Germany. ^[9] Neuromuscular Clinic and Research Center, Phoenix, AZ, USA. ^[10] Erasmus MC University Medical Center, Rotterdam, Netherlands. ^[11] Amicus Therapeutics, Inc., Princeton, NJ, USA. ^[12] University of California, Irvine, Irvine, CA, USA. ^[13]

DOI 10.1007/s00415-025-12899-3

PMID 39960520

发布时间 2025-02-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of neurology

2025年272卷3期

213页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).

Journal of neurology

相似文献

Journal of neurology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).

Journal of neurology

相似文献

Journal of neurology

相关期刊

检索历史清除